BioClinica snags a Pfizer exec to take the helm

BioClinica, fresh from its latest merger, has named a Pfizer ($PFE) executive as its next CEO. John Hubbard, who served as senior vice president and worldwide head of development operations at Pfizer, will take the reins on Jan. 5, when longtime chief Mark Weinstein will step down. Hubbard oversaw more than 450 clinical projects in his time at Pfizer, BioClinica said, and his CV includes stops at Icon ($ICLR), Parexel ($PRXL) and Hoechst Marion Roussel Pharmaceuticals, since acquired by Sanofi ($SNY). More

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.